Fingolimod mitigates synaptic deficits and psychosis‐like behavior in APP/PSEN1 mice

Abstract

Preclinical studies employing complementary psychosis-associated behavioral assessments and proteomic evaluations across multiple AD-related models are warranted to replicate the current study and further investigate fingolimod as a candidate treatment for psychosis in AD.